Bodal Chemicals Ltd Q1 FY26 Earnings Analysis
Published 30 May 2026 | Market Cap: ₹950 Cr
Price
₹67.7
Market Cap
₹950 Cr
P/E Ratio
13.8
Revenue Rank
Margin Rank
Earnings Summary
Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently. - Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment. - Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months. - Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26. - TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4. - Focusing on consolidating existing businesses with limited capex for next 2-3 years, mainly small debottlenecking. - Target to raise caustic soda capacity utilization to 90%-95% in coming quarters. - Export contributes ~22% of revenue; U.S. Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%.
📊 Revenue & Sales Performance
Rank 3- →Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently.
- →Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment.
- →Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months.
- →Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26.
- →TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4.
- →Focusing on consolidating existing businesses with limited capex for next 2-3 years, mainly small debottlenecking.
- →Target to raise caustic soda capacity utilization to 90%-95% in coming quarters.
- →Export contributes ~22% of revenue; U.S. export negligible (~1%).
📈 Profitability & Margins
Rank 2- →Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%.
- →EBITDA margin guidance is around 11% to 12%, corresponding to an operating income of about INR35 crores per quarter.
- →Net profit expected approx. INR70 to 80 crores for next year, implying 7% to 8% return on investment (ROI).
- →Two key businesses — benzene derivatives and TCCA — are expected to scale up in 3-6 months, contributing positively to margins and profitability.
- →Benzene business revenue expected to reach INR100 crores in FY26, potentially INR300 crores at full capacity next year.
- →Capacity utilization targets for chlor-alkali near 90-95% within a few quarters.
- →Improved pricing in TCCA anticipated by Q3/Q4 post import duty impact, helping margins further.
- →Debt reduction plan ongoing, targeting reduction of INR150-175 crores term debt by year-end, aiding financial health.
🏗️ Capital Expenditure Plans
No- →No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup.
- →Small debottlenecking or Brownfield expansions may happen but will be very limited in scale.
- →Strategic land sale of about 8 acres at Rajpura to a large chlorine consumer to develop pipeline chlorine buyers, not a real estate deal but a business collaboration.
- →The company has about 62 acres of surplus land for future expansions, ensuring capacity for growth over the next 10-15 years.
- →Future growth capex will be considered after achieving a targeted debt-to-EBITDA ratio near 2.5, indicating focus on debt reduction before new investments.
- →Emphasis on increasing capacity utilization and improving leverage profile before undertaking major capital investments.
💰 Fundraising & Capital Structure
No- →Currently, Bodal Chemicals is not targeting any major capex for the next couple of years, focusing instead on consolidating the current setup and improving utilization.
- →Small debottlenecking or minor brownfield expansions may occur, but nothing major requiring significant fundraising.
- →The company is actively aiming to reduce existing term debt by INR150-175 crores by the end of the current year through scheduled repayments and asset sales.
- →Targeted debt-to-EBITDA ratio is near 2.5; only after achieving this leverage profile will the company consider next growth plans.
- →There is no explicit mention of new equity fundraising in the transcript.
- →The focus is on improving profitability and reducing debt before planning any new fundraising for expansion.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Bodal Chemicals Ltd Q1 FY26 results?
Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently. - Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment. - Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months. - Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26. - TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4. - Focusing on consolidating existing businesses with limited capex for next 2-3 years, mainly small debottlenecking. - Target to raise caustic soda capacity utilization to 90%-95% in coming quarters. - Export contributes ~22% of revenue; U.S. Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%.
What is Bodal Chemicals Ltd share price analysis?
Bodal Chemicals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 13.8 with a market cap of ₹950 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bodal Chemicals Ltd planning capital expenditure?
No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.